Prevention of Lung Injury asociated with Acute Necrotizing Pancreatitis

Summary of the technology

CSIC has found the potential of polyethylene glycol on reducing the severity of acute necrotizing
pancreatitis and associated lung injury, thus minimizing the systemic inflammatory response.

Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent
licence agreement.
An offer for Patent Licensing

CSIC - Consejo Superior de Investigaciones Científicas

Protective role of PEG35 against ANP-associated inflammatory

processes Acute pancreatitis is associated to systemic complications, especially lung injury.
Acute pancreatitis, a sudden inflammatory disorder of the pancreas, is the leading cause of hospitalization for gastrointestinal diseases. Up to 20% of patients develop acute necrotizing pancreatitis (ANP), the more aggressive form, which is associated with local and systemic complications. These systemic complications are the cause of the substantial morbidity and mortality rates in ANP, especially for the lung injury that accounts for 60% of all deaths within the first week.
At present, there is no specific medical treatment for ANP. The management of the disease is mainly supportive and targeted to prevent and treat systemic complications.
Polyethylene glycols (PEGs) are non-immunogenic, non-toxic and water- soluble polymers. These properties render the polymer ideally suited for biological applications.
PEG of 35-kDa molecular weight (PEG35) has been tested in vivo in an experimental model of ANP in rats. Its prophylactic administration abrogated ANP-associated local and systemic inflammatory process. Notably, therapeutic treatment directly lowered the lung injury regardless of the pancreatic lesion.

Main innovations and advantages

· PEG35 has shown capacity to strongly reduce the severity of ANP andameliorate the associated lung failure, the main contributing factor toearly death in patients with this condition.
· PEG35 exerts an anti-inflammatory role in ANP by downregulating pro-inflammatory cytokines (IL6, IL1β, TNF-) and chemokines (CXCL2),adhesion molecules (P-selectin and ICAM1), as well as neutrophilinfiltration.
· PEG35 protects against inflammation-induced cell death in ANP.
· PEG35 could be a promising tool for the modulation of the progressionof ANP towards a lethal outcome.

Intellectual property status

  • Granted Patent
  • Patent application number :-

Related Keywords

  • Biological Sciences
  • Medicine, Human Health
  • Medical Technology / Biomedical Engineering
  • lung injury

About CSIC - Consejo Superior de Investigaciones Científicas

The Spanish National Research Council (in Spanish 'Consejo Superior de Investigaciones Científicas (CSIC)') is a government agency for basic and applied scientific research.

It is the largest public research organization in Spain, with presence in all the Autonomous Communities through 126 centers and 145 associated units.

CSIC - Consejo Superior de Investigaciones Científicas

Never miss an update from CSIC - Consejo Superior de Investigaciones Científicas

Create your free account to connect with CSIC - Consejo Superior de Investigaciones Científicas and thousands of other innovative organizations and professionals worldwide

CSIC - Consejo Superior de Investigaciones Científicas

Send a request for information
to CSIC - Consejo Superior de Investigaciones Científicas

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.


Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support